Astrazeneca (AZN) Equity Income (2009 - 2022)
Astrazeneca (AZN) posted quarterly Equity Income of $1.0 million for Q3 2022, up 114.29% year-over-year from $466666.7 in Q3 2021, and up 114.29% quarter-over-quarter from -$7.0 million in Q3 2021.
Astrazeneca (AZN) Equity Income (2009 - 2022) Analysis & Trends
Astrazeneca's Equity Income history runs 6 years deep, the most recent figure standing at $1.0 million for Q3 2022.
- In Q3 2022, Equity Income rose 114.29% year-over-year to $1.0 million; the TTM figure through Sep 2022 stood at $4.9 billion (down 53.07% YoY), while the FY2014 annual figure was $1.5 billion, changed N/A from the prior year.
- Equity Income for Q3 2022 stood at $1.0 million, up from -$7.0 million in the prior quarter.
- The five-year high for Equity Income was $1.0 million in Q3 2022, with the low at -$7.0 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -2.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -10.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -4.03 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -10.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 1.00 Mn |
| Sep 30, 2021 | -7.00 Mn |
| Dec 31, 2012 | 2.40 Bn |
| Dec 31, 2011 | 2.50 Bn |
| Dec 31, 2010 | 5.53 Bn |
| Dec 31, 2009 | 7.10 Bn |